Background: The aim of the study was to evaluate the achievement of ‘no evidence of disease activity’ (NEDA) over a 12-month period in a large multicenter population with relapsing remitting multiple sclerosis (RRMS) treated with delayed-release dimethyl fumarate (DMF) and teriflunomide (TRF) using a propensity-score adjustment. Methods: A time-to-event method was used to determine the percentages of patients with RRMS (pwRRMS) in both groups achieving NEDA 3 (no relapses, no 12-week confirmed disability progression, and no new T2/gadolinium-enhancing brain lesions). We described the safety profile of the investigated drugs. Results: Of the 587 pwRRMS treated with DMF and the 316 pwRRMS treated with TRF, 468 pwRRMS were successfully paired by propensity score: 234 on DMF and 234 on TRF. The percentages of pwRRMS who achieved NEDA 3 were 80.3% in the DMF group and 77.2% in the TRF group. Serious adverse events occurred in four (1.9%) pwRRMS on DMF and in three (1.3%) pwRRMS on TRF. Conclusions: DMF and TRF significantly impacted RRMS disease activity in our study. Serious safety concerns were recorded in less than 2% of the studied population.

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in relapsing-remitting Multiple sclerosis. an Italian real-word multicenter experience / D’Amico, Emanuele; Zanghì, Aurora; Callari, Graziella; Borriello, Giovanna; Gallo, Antonio; Graziano, Giusi; Valentino, Paola; Buccafusca, Maria; Cottone, Salvatore; Salemi, Giuseppe; Ragonese, Paolo; Bossio, Roberto Bruno; Docimo, Renato; Grimaldi, Luigi Maria Edoardo; Pozzilli, Carlo; Tedeschi, Gioacchino; Zappia, Mario; Patti, Francesco. - In: THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. - ISSN 1756-2856. - 11:(2018), pp. 1-14. [10.1177/1756286418796404]

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in relapsing-remitting Multiple sclerosis. an Italian real-word multicenter experience

Borriello, Giovanna;Pozzilli, Carlo;
2018

Abstract

Background: The aim of the study was to evaluate the achievement of ‘no evidence of disease activity’ (NEDA) over a 12-month period in a large multicenter population with relapsing remitting multiple sclerosis (RRMS) treated with delayed-release dimethyl fumarate (DMF) and teriflunomide (TRF) using a propensity-score adjustment. Methods: A time-to-event method was used to determine the percentages of patients with RRMS (pwRRMS) in both groups achieving NEDA 3 (no relapses, no 12-week confirmed disability progression, and no new T2/gadolinium-enhancing brain lesions). We described the safety profile of the investigated drugs. Results: Of the 587 pwRRMS treated with DMF and the 316 pwRRMS treated with TRF, 468 pwRRMS were successfully paired by propensity score: 234 on DMF and 234 on TRF. The percentages of pwRRMS who achieved NEDA 3 were 80.3% in the DMF group and 77.2% in the TRF group. Serious adverse events occurred in four (1.9%) pwRRMS on DMF and in three (1.3%) pwRRMS on TRF. Conclusions: DMF and TRF significantly impacted RRMS disease activity in our study. Serious safety concerns were recorded in less than 2% of the studied population.
2018
dimethyl fumarate; efficacy; no evidence of disease activity 3; safety; teriflunomide; pharmacology; neurology; neurology (clinical)
01 Pubblicazione su rivista::01a Articolo in rivista
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in relapsing-remitting Multiple sclerosis. an Italian real-word multicenter experience / D’Amico, Emanuele; Zanghì, Aurora; Callari, Graziella; Borriello, Giovanna; Gallo, Antonio; Graziano, Giusi; Valentino, Paola; Buccafusca, Maria; Cottone, Salvatore; Salemi, Giuseppe; Ragonese, Paolo; Bossio, Roberto Bruno; Docimo, Renato; Grimaldi, Luigi Maria Edoardo; Pozzilli, Carlo; Tedeschi, Gioacchino; Zappia, Mario; Patti, Francesco. - In: THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS. - ISSN 1756-2856. - 11:(2018), pp. 1-14. [10.1177/1756286418796404]
File allegati a questo prodotto
File Dimensione Formato  
D'amico_comparable-efficacy-and-safety_2018.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 698.68 kB
Formato Adobe PDF
698.68 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1225820
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 32
social impact